CA-NETAPP
1.12.2021 14:02:14 CET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced new innovations in its product portfolio as well as award recognition from Amazon Web Services (AWS) for its achievements as an AWS Partner. Together, these announcements demonstrate how NetApp's investments and vision are enabling any organization using AWS to access world-class cloud operations (CloudOps) and maximize the value of their investment.
At AWS re:Invent this week, NetApp was named the 2021 AWS Independent Software Vendor (ISV) Design Partner of the Year - US, for the jointly engineered and natively integrated Amazon FSx for NetApp ONTAP service. This fully-managed, multi-protocol storage service from AWS allows organizations to extend on-premises data onto AWS for enhanced data protection, migrate enterprise workloads without refactoring, and set the stage to run stateful Kubernetes applications. The award recognizes NetApp’s work in helping customers enable innovation and build solutions that drive digital and cloud transformation on the AWS Cloud.
“AWS Partners are critical to our customers’ success, and we are pleased to recognize NetApp as a 2021 AWS Partner of the Year US winner,” said Rachel Mushahwar, Head of Channel and Partner Sales - Americas, AWS. “I continue to be impressed by the commitment and innovation that NetApp offers our customers and how they are uniquely positioned to help accelerate our customers’ digital transformation journey. I look forward to working together and a great 2022.”
“We are proud to be named the AWS ISV Design Partner of the Year in the US," said Anthony Lye, Executive Vice President and General Manager of Public Cloud Services at NetApp. "For nearly a decade, NetApp and AWS engineers have worked together to create industry-leading cloud services, so it's incredibly exciting to see our joint innovation be recognized onstage at this year’s re:Invent. Together, NetApp and AWS are delivering the best of cloud to our customers and partners to deliver immediate business value, whether in the form of cost efficiency, compliance, data protection, or performance."
NetApp also announced important milestones in the growth of its Spot by NetApp product portfolio for CloudOps, including:
Spot Ocean for Apache Spark
Part of the Spot Ocean suite of products, Spot Ocean for Apache Spark combines the infrastructure automation and optimization of Spot Wave together with Data Mechanics, recently acquired by NetApp, to give data infrastructure teams the power and flexibility of Apache Spark on Kubernetes without the complexity of managing and tuning infrastructure and workloads. Ocean for Apache Spark
is now available in preview for AWS customers.
Spot Ocean Continuous Delivery (CD)
Also, part of the Spot Ocean suite, Spot Ocean CD extends Spot by NetApp’s core technologies with a solution for easy, reliable delivery of cloud-native applications on Kubernetes. Available for private preview with AWS customers in mid-December, Spot Ocean CD
makes it easy to quickly and reliably execute deployments with integrated and automated continuous verification to give developers full confidence in their deployments.
Together with Spot Ocean serverless infrastructure, these products make up the expanded Spot Ocean suite, bringing intelligent automation and optimization to cloud-native infrastructure and workloads on Kubernetes.
CloudCheckr Well-Architected Readiness Advisor
CloudCheckr, recently acquired by NetApp, complements the Spot product portfolio to expand Spot by NetApp’s financial operations (FinOps) capabilities. Spot by NetApp today announced the release of CloudCheckr Well-Architected Readiness Advisor, which helps managed service providers (MSPs) streamline the process of delivering AWS Well-Architected Reviews and helps to ensure that AWS customers are in compliance with the AWS Well-Architected Framework for optimization of cloud cost, security, operations, performance and reliability.
The Well-Architected Readiness Advisor is available on the CloudCheckr CMx platform.
Spot Security
Spot Security enables customers to quickly detect, prioritize and help mitigate the most serious security threats and risks within cloud infrastructure. Spot Security
is now available in private preview, starting with AWS customers.
“Getting applications to the cloud is only the first step in the cloud journey,” said Amiram Shachar, Vice President and General Manager of Spot by NetApp. “Realizing the promise of cloud requires a holistic approach to operating within the cloud, an approach that addresses cost, resource management, optimization and security. Our growing portfolio delivers a compelling suite of solutions for cloud operations that let organizations focus on their applications rather than on infrastructure.”
Additional Resources:
- Spot Ocean Suite Blog
- Spot Ocean for Apache Spark Blog
- CloudCheckr Well-Architected Readiness Advisor Blog
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com
or follow us on Twitter
, LinkedIn
, Facebook
, and Instagram
.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005381/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
